MATTEO UGGERI

Dr. MATTEO UGGERI

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AOAlessandro Orro
Alessandro Orro
MUMATTEO UGGERI
MATTEO UGGERI
MRMarco Rusnati
Marco Rusnati
CUChiara Urbinati
Chiara Urbinati
NPNicoletta Pedemonte
Nicoletta Pedemonte
Pasqualina D'ursiPasqualina D'ursi
Pasqualina D'ursi

28 June 2024 in Viruses
Verified
Journal Article
Open access
PDF file
Pasqualina D'ursiPasqualina D'ursi
Pasqualina D'ursi
Alessandro RondinaAlessandro Rondina
Alessandro Rondina
AZAlberto Zani
Alberto Zani
MUMATTEO UGGERI
MATTEO UGGERI
SMSerena Messali
Serena Messali
FCFrancesca Caccuri
Francesca Caccuri
The human immunodeficiency virus (HIV-1) matrix protein p17 (p17) is released from infected cells as a protein capable of deregulating the biological activity of different cells. P17 variants (vp17s), more frequently detected in the plasma of HIV-1+ patients with rather than without lymphoma and characterized by amino acids insertions in their C-terminal region, were found to trigger B cell growth and clonogenicity. Vp17s endowed with B-cell-growth-promoting activity are drastically destabilized, whereas, in a properly folded state, reference p17 (refp17) does not exert any biological activity on B cell growth and clonogenicity. However, misfolding of refp17 is necessary to expose a masked functional epitope, interacting with the protease-activated receptor 1 (PAR-1), endowed with B cell clonogenicity. Indeed, it is worth noting that changes in the secondary structure can strongly impact the function of a protein. Here, we performed computational studies to show that the gain of function of vp17s is linked to dramatic conformational changes due to structural modification in the secondary-structure elements and in the rearrangement of the hydrogen bond (H-bond) network. In particular, all clonogenic vp17s showed the disengagement of two critical residues, namely Trp16 and Tyr29, from their hydrophobic core. Biological data showed that the mutation of Trp16 and Tyr29 to Ala in the refp17 backbone, alone or in combination, resulted in a protein endowed with B cell clonogenic activity. These data show the pivotal role of the hydrophobic component in maintaining refp17 stability and identify a novel potential therapeutic target to counteract vp17-driven lymphomagenesis in HIV-1+ patients.

22 January 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
ABAnna Bertelli
Anna Bertelli
MUMATTEO UGGERI
MATTEO UGGERI
FFFederica Filippini
Federica Filippini
MDMelissa Duheric
Melissa Duheric
FCFrancesca Caccuri
Francesca Caccuri
ACArnaldo Caruso
Arnaldo Caruso
The U94 protein of Human Herpesvirus 6 exerts antiproliferative effects through downregulation of the Src proto-oncogene. We aimed to define the shortest U94 fragment that preserves antiproliferative activity and to explore its structural properties. U94 was truncated into shorter fragments, which were subjected to computational analyses and proliferation assays on MDA-MB-468, BT-549 breast cancer cells. Src phosphorylation levels were scrutinized by Western blot analysis. Data obtained demonstrated that the U94 antiproliferative activity resides in its N-terminal region. Specifically, MT153 (aa 1–153) and MT117 (aa 1–117) fragments exhibited antiproliferative activity, whereas MV85 (aa 1–85) fragment did not. Computational analyses identified MG112 (aa 1–112) and MI108 (aa 1–108) as biologically active and suggested that the β-sheet of the structure is critical. The shortest KI95 fragment (aa 14–108), maintaining a stable β-sheet, demonstrated antiproliferative effects and Src downregulation. The antiproliferative activity of U94 and its active fragments relies on stable tridimensional conformation rather than on linear peptide sequence. KI95 represents the shortest active U94 fragment that preserves biological function, with critical residues likely located within the β-sheet region. These findings highlight the importance of structural integrity in U94 functionality and suggest KI95 as a potential therapeutic agent for cancer treatment.